XENETIC BIOSCIENCES INC
XBIONASDAQTrading Snapshot
- Day Range
- $2.27 – $2.31
- 52-Week Range
- $1.87 – $13.93
- Volume
- $2.03B
- Avg Volume
- $1.66B
- Shares Outstanding
- 2.3M
- Next Earnings
- Nov 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $660,601
- P/E Ratio
- -1.9
- P/S Ratio
- 1.6x
- EPS (TTM)
- $-1.08
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +48.6%
Why Investors Own XBIO
- ✓High-growth profile — revenue up +25.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
XENETIC BIOSCIENCES INC
XBIO
StockOtter · stockotter.spaceAbout XENETIC BIOSCIENCES INC
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Financial Contrast: Xenetic Biosciences (NASDAQ:XBIO) & Allarity Therapeutics (NASDAQ:ALLR)
Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies
Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks Transcript
Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks Transcript
Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition
Xenetic Biosciences Inc. (NASDAQ:XBIO) on Wednesday struck a definitive share exchange agreement to purchase Santersus AG, a privately held therapeutic medical device firm advancing its selective blood purification platf
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune disease, transplant
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategy Ongoing generation of translational data designed to support future clinical development and deepen understanding o